Cargando…

DIPG-17. CD155 regulates cell growth and immune evasion in diffuse intrinsic pontine glioma

There is an unmet need for more effective treatment strategies for diffuse intrinsic pontine glioma (DIPG), a devastating brain tumour arising in children and young adults. While immunotherapy is emerging as a powerful approach to treatment of other cancers, clinical trials with immune checkpoint in...

Descripción completa

Detalles Bibliográficos
Autores principales: Tzaridis, Theophilos, Eisemann, Tanja, Andrade, Augusto F, Hope, Jennifer L, Romero, Megan M, Becher, Oren J, Jabado, Nada, Bradley, Linda M, Wechsler-Reya, Robert J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164992/
http://dx.doi.org/10.1093/neuonc/noac079.074
_version_ 1784720279113564160
author Tzaridis, Theophilos
Eisemann, Tanja
Andrade, Augusto F
Hope, Jennifer L
Romero, Megan M
Becher, Oren J
Jabado, Nada
Bradley, Linda M
Wechsler-Reya, Robert J
author_facet Tzaridis, Theophilos
Eisemann, Tanja
Andrade, Augusto F
Hope, Jennifer L
Romero, Megan M
Becher, Oren J
Jabado, Nada
Bradley, Linda M
Wechsler-Reya, Robert J
author_sort Tzaridis, Theophilos
collection PubMed
description There is an unmet need for more effective treatment strategies for diffuse intrinsic pontine glioma (DIPG), a devastating brain tumour arising in children and young adults. While immunotherapy is emerging as a powerful approach to treatment of other cancers, clinical trials with immune checkpoint inhibitors have failed to show a survival benefit for DIPG patients. In this study, we analysed the expression of immune checkpoint molecules on the surface of human and murine DIPG cells by flow cytometry and identified CD155 and B7-H3 as the most highly expressed checkpoint molecules, with minimal expression of PD-L1, PD-L2, Galectin-9, CEACAM-1, CD86, CD252 and CD137. These findings were confirmed in primary patient samples from pediatric brain tumours, including high-grade gliomas, medulloblastomas and ependymomas. To test whether CD155 inhibition increases susceptibility to CD8+ T cell killing in vitro, we cultured DIPG cells expressing ovalbumin (OVA) with CD8+ T cells from OT-I mice, which express T cell receptors specific for OVA. Addition of CD155 blocking antibodies to these cultures increased expression of T cell activation markers (CD25, CD44 and CD69) as well as T cell-mediated tumour killing, supporting the notion that CD155 can function as an immune checkpoint in DIPG. In addition to its effects on T cells, CD155 also exerted direct effects on tumour cells: treatment with anti-CD155 antibodies led to impaired cell viability, and shRNA-mediated knockdown of CD155 resulted in reduced cell proliferation in vitro. Strikingly, knockdown of CD155 also led to reduced growth of DIPG cells in vivo, and mice transplanted with the CD155-deficient cells had a clear survival benefit compared to mice transplanted with wild type cells. These studies demonstrate that CD155 functions as an immune checkpoint and as a regulator of tumor growth in DIPG, and suggest that targeting CD155 could be a valuable therapeutic strategy for this devastating disease.
format Online
Article
Text
id pubmed-9164992
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91649922022-06-05 DIPG-17. CD155 regulates cell growth and immune evasion in diffuse intrinsic pontine glioma Tzaridis, Theophilos Eisemann, Tanja Andrade, Augusto F Hope, Jennifer L Romero, Megan M Becher, Oren J Jabado, Nada Bradley, Linda M Wechsler-Reya, Robert J Neuro Oncol Diffuse Midline Glioma/DIPG There is an unmet need for more effective treatment strategies for diffuse intrinsic pontine glioma (DIPG), a devastating brain tumour arising in children and young adults. While immunotherapy is emerging as a powerful approach to treatment of other cancers, clinical trials with immune checkpoint inhibitors have failed to show a survival benefit for DIPG patients. In this study, we analysed the expression of immune checkpoint molecules on the surface of human and murine DIPG cells by flow cytometry and identified CD155 and B7-H3 as the most highly expressed checkpoint molecules, with minimal expression of PD-L1, PD-L2, Galectin-9, CEACAM-1, CD86, CD252 and CD137. These findings were confirmed in primary patient samples from pediatric brain tumours, including high-grade gliomas, medulloblastomas and ependymomas. To test whether CD155 inhibition increases susceptibility to CD8+ T cell killing in vitro, we cultured DIPG cells expressing ovalbumin (OVA) with CD8+ T cells from OT-I mice, which express T cell receptors specific for OVA. Addition of CD155 blocking antibodies to these cultures increased expression of T cell activation markers (CD25, CD44 and CD69) as well as T cell-mediated tumour killing, supporting the notion that CD155 can function as an immune checkpoint in DIPG. In addition to its effects on T cells, CD155 also exerted direct effects on tumour cells: treatment with anti-CD155 antibodies led to impaired cell viability, and shRNA-mediated knockdown of CD155 resulted in reduced cell proliferation in vitro. Strikingly, knockdown of CD155 also led to reduced growth of DIPG cells in vivo, and mice transplanted with the CD155-deficient cells had a clear survival benefit compared to mice transplanted with wild type cells. These studies demonstrate that CD155 functions as an immune checkpoint and as a regulator of tumor growth in DIPG, and suggest that targeting CD155 could be a valuable therapeutic strategy for this devastating disease. Oxford University Press 2022-06-03 /pmc/articles/PMC9164992/ http://dx.doi.org/10.1093/neuonc/noac079.074 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Diffuse Midline Glioma/DIPG
Tzaridis, Theophilos
Eisemann, Tanja
Andrade, Augusto F
Hope, Jennifer L
Romero, Megan M
Becher, Oren J
Jabado, Nada
Bradley, Linda M
Wechsler-Reya, Robert J
DIPG-17. CD155 regulates cell growth and immune evasion in diffuse intrinsic pontine glioma
title DIPG-17. CD155 regulates cell growth and immune evasion in diffuse intrinsic pontine glioma
title_full DIPG-17. CD155 regulates cell growth and immune evasion in diffuse intrinsic pontine glioma
title_fullStr DIPG-17. CD155 regulates cell growth and immune evasion in diffuse intrinsic pontine glioma
title_full_unstemmed DIPG-17. CD155 regulates cell growth and immune evasion in diffuse intrinsic pontine glioma
title_short DIPG-17. CD155 regulates cell growth and immune evasion in diffuse intrinsic pontine glioma
title_sort dipg-17. cd155 regulates cell growth and immune evasion in diffuse intrinsic pontine glioma
topic Diffuse Midline Glioma/DIPG
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164992/
http://dx.doi.org/10.1093/neuonc/noac079.074
work_keys_str_mv AT tzaridistheophilos dipg17cd155regulatescellgrowthandimmuneevasionindiffuseintrinsicpontineglioma
AT eisemanntanja dipg17cd155regulatescellgrowthandimmuneevasionindiffuseintrinsicpontineglioma
AT andradeaugustof dipg17cd155regulatescellgrowthandimmuneevasionindiffuseintrinsicpontineglioma
AT hopejenniferl dipg17cd155regulatescellgrowthandimmuneevasionindiffuseintrinsicpontineglioma
AT romeromeganm dipg17cd155regulatescellgrowthandimmuneevasionindiffuseintrinsicpontineglioma
AT becherorenj dipg17cd155regulatescellgrowthandimmuneevasionindiffuseintrinsicpontineglioma
AT jabadonada dipg17cd155regulatescellgrowthandimmuneevasionindiffuseintrinsicpontineglioma
AT bradleylindam dipg17cd155regulatescellgrowthandimmuneevasionindiffuseintrinsicpontineglioma
AT wechslerreyarobertj dipg17cd155regulatescellgrowthandimmuneevasionindiffuseintrinsicpontineglioma